Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) was up 2.1% during trading on Thursday . The company traded as high as $22.12 and last traded at $21.83, with a volume of 317,586 shares traded. The stock had previously closed at $21.38.

A number of equities research analysts recently commented on SUPN shares. Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 6th. Jefferies Group restated a “buy” rating and set a $23.00 price objective (up from $19.00) on shares of Supernus Pharmaceuticals in a report on Thursday, May 12th. Piper Jaffray Cos. lowered shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 price objective on the stock. in a report on Monday, July 18th. Finally, Northland Securities lowered shares of Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price objective on the stock. in a report on Monday, July 18th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $24.50.

The firm’s 50-day moving average price is $22.07 and its 200-day moving average price is $18.24. The firm has a market capitalization of $1.09 billion and a price-to-earnings ratio of 44.96.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.05. The business had revenue of $50.40 million for the quarter, compared to the consensus estimate of $49.67 million. The company’s revenue was up 43.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.03 earnings per share. On average, analysts forecast that Supernus Pharmaceuticals Inc. will post $0.68 EPS for the current year.

In other news, CFO Gregory S. Patrick sold 3,395 shares of the company’s stock in a transaction on Thursday, July 14th. The shares were sold at an average price of $22.00, for a total value of $74,690.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.